APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Trial Profile

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to an Alnylam Pharmaceuticals media release, full results are expected to be presented in late 2017 at the 1st European ATTR Amyloidosis Meeting for Patients and Doctors Nov 2017.
    • 09 Aug 2017 According to an Alnylam Pharmaceuticals media release, company expects to report top-line results in the coming weeks.
    • 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, top-line results from this trial are expected in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top